🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Distress Financial Stress SEC Filings — July 17, 2026

The July 17, 2026, digest reveals a severe micro-cap distress cluster, with five companies simultaneously facing Nasdaq delisting or receivership, signaling a potential liquidity and compliance crisis in the small-cap biotech and fintech sectors. Period-over-period data from the filings shows a universal pattern of deteriorating equity bases and market values, with no company reporting positive revenue growth or margin improvement. The most critical development is Fuse Science's complete insolvency and court-ordered receivership, which sets a precedent for aggressive creditor action against shell-like entities. A portfolio-level pattern emerges where four of the five companies (Dare Bioscience, Actuate Therapeutics, Caring Brands, Fold Holdings) are all in the same 180-day compliance window, creating a binary catalyst calendar in January 2027. The absence of any insider buying or positive forward guidance across all filings confirms a complete lack of management confidence, making these high-risk, low-recovery situations for equity holders.

5 high priority 5 total filings
· daily

Global High-Priority Regulatory Events — July 17, 2026

The July 17, 2026, filing set reveals a market dominated by corporate restructuring, insolvency proceedings, and strategic M&A, with a notable concentration of distress in Indian real estate and financial services. Key period-over-period trends include significant revenue declines from asset sales (Braemar Hotels: -18% pro forma revenue drop) and margin compression from regulatory penalties (Jana Small Finance Bank: 22.5% NPA divergence). The most critical developments are the appointment of a receiver for Fuse Science (insolvent, $0 assets), Nasdaq delisting threats for Actuate Therapeutics and Dare Bioscience, and a transformative 99% capital reduction at Oxford Industries following a change in control. Portfolio-level patterns show a surge in SPAC activity (4 IPOs/amendments) and a wave of Indian insolvency updates (7 filings), signaling a bifurcated market where capital is flowing to new blank-check vehicles while legacy entities face liquidation or restructuring. The overall sentiment is cautiously negative, with 18 filings carrying negative or mixed sentiment, but pockets of opportunity exist in renewable energy (DCM Shriram) and aerospace (NRB Bearing).

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — July 17, 2026

Across 50 SEC filings for July 17, 2026, three dominant themes emerge: (1) pronounced capital actions and M&A activity driving near-term catalysts (Dominion/NextEra S-4 filings, IPG/Lumibird bid, Jasper/Kira all‑stock + PIPE, multiple SPAC IPOs/extensions); (2) mixed financial performance across banks and industrials with earnings dispersion — regional banks show resilient fee income but margin pressure (Truist, Regions, Fifth Third), while select industrials/energy report restructuring charges and asset impairments (Autoliv, Frequency Electronics, BHP); (3) significant dilution and financing maneuvers at smaller growth/tech names (AITX reverse split and share regime changes, NovaBridge equity plan, multiple SPACs). Period-over-period comparisons show revenue growth >20% YoY in pockets (AITX device rental +37% driving +26% revenue YoY), while several companies report margin compression (Frequency Electronics gross margin down ~1,400 bps YoY to 29.1%). Material developments with market implications: Dominion/NextEra combination (expected close H2 2027) is the largest regulatory/catalyst event and may re-rate regulated utility exposures; Jasper/Kira transaction materially dilutes legacy holders but funds operations into 2H 2028 and creates a biotech pipeline with milestone CVR upside; IPG’s €300M Lumibird Medical offer is accretive to margin and expands medical laser exposure. Portfolio-level patterns: SPAC activity remains elevated (multiple new IPOs, unit separations, deadline extensions) signaling continuing sponsor-driven deal flow; insider moves are meaningful in select filings (Jefferies large buy by SMFG, exercises by directors) and indicate conviction in financials or compensation settlements. Immediate market actions should prioritize monitorable near-term catalysts (Dominion regulatory filings, IPG close expected Q4 2026, Jasper clinical milestones to 2028, MakeMyTrip Indian IPO process) while de-risking names with cash erosion, high short-term liabilities, or ongoing deregistration filings (Sigyn, AITX liquidity stress).

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — July 17, 2026

The single filing for eBay Inc. (EBAY) within the S&P 500 Consumer Discretionary stream reveals a major, high-conviction event: GameStop Corp. has disclosed a 9.8% beneficial ownership stake, acquired through a combination of open-market purchases and the physical settlement of a massive derivatives position. The total consideration of approximately $4.35 billion underscores a significant capital deployment by a fellow consumer discretionary company into a legacy e-commerce platform. This event creates a unique dynamic, blending activist-like positioning with potential strategic or financial motives. The filing's materiality is high (8/10), but the lack of period-over-period comparisons, insider trading, or forward guidance from eBay itself limits the breadth of traditional fundamental analysis. The key takeaway is the emergence of a new, influential shareholder with a history of disruptive moves, which could catalyze strategic changes at eBay.

1 high priority 1 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — July 17, 2026

The four filings from the S&P 500 Healthcare stream reveal a clear insider conviction signal in the managed care segment, with Elevance Health's CEO and a director making significant open-market purchases totaling over $1.1 million. This insider buying, occurring at a stock price near $366-368, suggests management sees the company as undervalued, especially given the CEO's already substantial 171,976-share holding. In contrast, the two Vertex Pharmaceuticals filings show routine director compensation in deferred stock units, carrying no market signal. The absence of any period-over-period financial comparisons, forward guidance, or capital allocation changes across these filings limits the ability to identify broader sector trends. The primary actionable insight is the concentrated bullish insider activity at Elevance Health, which warrants further investigation into the company's fundamentals and upcoming catalysts.

4 high priority 4 total filings
· daily

US Earnings Financial Results SEC Filings — July 17, 2026

This digest covers 10 filings with enriched data, revealing a market dominated by mixed earnings quality and diverging capital allocation strategies. While revenue growth is present across several companies (Netflix +13.4% YoY, Paychex +17% YoY, Cloudastructure +78% YoY), profitability is under severe pressure. A clear theme of 'growth at a cost' emerges, with operating expenses and interest costs surging, compressing margins for Autoliv, Paychex, and Frequency Electronics. The most critical development is the aggressive capital return programs at Travelers ($3.1B buybacks, +13.6% dividend) and Netflix ($4.71B in Q2 buybacks), signaling strong management confidence despite operational headwinds. Conversely, micro-cap companies like Winning Catering and Snow Rothschild show extreme financial fragility with zero cash and negative equity. Insider activity data was notably absent from these filings, limiting one key signal source, but the period-over-period comparisons and forward-looking statements provide a rich tapestry of actionable intelligence. The overall picture is one of a bifurcated market where large caps are returning capital aggressively, while smaller and mid-cap firms struggle with rising costs and margin compression, creating both risks and potential turnaround opportunities.

10 high priority 10 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 17, 2026

This intelligence stream covers six SEC proxy filings from July 17, 2026, spanning blank-check companies (Cartesian Growth Corp II, SilverBox Corp IV), a regional bank (Riverview Bancorp), and three biotech/life-sciences firms (Tempest Therapeutics, Tivic Health Systems, Glucotrack). The dominant theme is corporate survival and restructuring: two SPACs seek deadline extensions to consummate deals, two micro-cap biotechs propose reverse stock splits to maintain Nasdaq listings, and one biotech seeks governance changes to eliminate supermajority voting. Period-over-period data is sparse across these filings, as most are special-meeting proxies rather than annual reports with financial comparisons. However, insider ownership is notably high in the SPACs (Cartesian: ~65.1% insider voting power), and insider trading activity is absent in all filings—no CEO or CFO transactions were reported. The most material development is Tivic Health's existential Nasdaq delisting risk (stock at $0.52, 90% below the $1.00 threshold), while Glucotrack's post-merger reverse split (up to 1-for-30) signals aggressive capital structure restructuring. No sector-wide trends emerge given the diverse company types, but a common thread is shareholder dilution risk across three of the six companies. The overall sentiment is neutral-to-negative, with no bullish signals identified.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 17, 2026

The IPO pipeline on July 17, 2026, is heavily concentrated in pre-revenue biopharmaceutical and life sciences companies, with 7 of 8 filings (NuvOx, Latigo, Tivic/Valion, TG-17, Biovie, Alpha Modus, Propanc) coming from this sector. A common theme across these issuers is significant accumulated deficits, negative cash flows, and complex capital structures involving multiple series of convertible preferred stock, warrants, and related-party debt. The lone non-biotech filing is an S-4 merger registration for Bank First Corp's acquisition of PSB Holdings, representing a more mature, revenue-generating entity. Period-over-period data from the filings reveals that all biotech issuers are pre-revenue with no YoY revenue growth, and their net losses are widening (e.g., Biovie's net loss of $12.5M for the nine months ended March 31, 2026). Insider trading activity is absent in these filings, but forward-looking statements uniformly highlight going concern risks and reliance on future financing. The most critical development is the sheer volume of biotech IPOs hitting the market on the same day, which could signal a sector-wide push to access public markets amid a favorable window, but also raises concerns about quality and investor selectivity.

8 high priority 8 total filings
· daily

US SEC Trading Suspension Halt Orders — July 17, 2026

On July 17, 2026, four Nasdaq-listed micro-cap companies disclosed imminent delisting or non-compliance risks, signaling a concentrated wave of regulatory enforcement against companies with deteriorating financial health. All four filings carry negative sentiment and high materiality (8-9/10), with common themes of insufficient stockholders' equity, collapsing market values, and sub-$1.00 bid prices. Period-over-period comparisons from the enriched data reveal that Dare Bioscience and Caring Brands both failed the same $2.5M stockholders' equity threshold, while Actuate Therapeutics saw its Market Value of Listed Securities (MVLS) fall below $50M starting June 1, 2026, and Fold Holdings breached the $1.00 minimum bid price for 30 consecutive days. No insider buying or capital allocation actions (dividends, buybacks) were reported across any of the four companies, underscoring severe financial distress and lack of management confidence. The most critical development is Caring Brands' imminent trading suspension deadline of July 24, 2026, if it fails to request a hearing by July 22, 2026—making it the highest-urgency situation. These filings collectively highlight a sector-wide purge of financially weak micro-caps from Nasdaq, with implications for liquidity risk, forced selling, and potential complete loss of equity value for shareholders.

4 high priority 4 total filings
· daily

US Executive Officer Management Changes SEC — July 17, 2026

This digest of 42 filings reveals a significant wave of executive and board-level changes across US-listed companies, with a notable concentration in the small-cap and micro-cap space. Key themes include a high volume of CFO departures and appointments, several board refreshments bringing in specialized expertise (e.g., sustainable investing, SPAC experience), and a few instances of leadership transitions tied to M&A or strategic pivots. Period-over-period data is largely absent from these event-driven filings, but forward-looking statements and insider activity provide actionable insights. The most critical developments include a CFO appointment at Energy Vault from a top-tier firm, a CEO salary increase at Star Group, and a leadership overhaul at Raphael Pharmaceutical, which carries the highest risk. Overall, the period is characterized by routine governance changes, but several filings present clear bullish or bearish signals for investors.

42 high priority 42 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 17, 2026

Fuse Science, Inc. has entered a formal insolvency proceeding with the appointment of a receiver by the Clark County District Court, marking a definitive end to its operational viability. The company reported zero assets and zero cash as of December 31, 2026, and has relocated its headquarters and assets abroad, signaling a complete capital erosion. The receiver has been granted sweeping authority to investigate insider transactions, claw back improperly issued shares, and wind down the business, which introduces significant legal and reputational risk for former insiders. This filing represents a total loss for equity holders and underscores the severe consequences of sustained operational failure and potential governance lapses. The lack of any period-over-period improvements, forward guidance, or insider buying reinforces the terminal nature of this situation, making it a clear cautionary case for distressed-debt and event-driven investors.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 17, 2026

The 42 filings reveal a busy day for board and officer changes, with 28 separate appointments or departures across 19 companies. Most changes are routine, but several carry strategic significance: Energy Vault's appointment of a BlackRock veteran as CFO hints at a push toward commercial-scale capital raising, while Bunker Hill Mining's affirmative ESG rating and mine restart progress suggest an operational inflection point. Period-over-period data, though sparse in many filings, shows Karyopharm Therapeutics implementing a $3.7 million cash retention program, replacing a bonus plan to lock in key talent during a catalyst-rich period. Overall, the tone is neutral-to-positive, with only one clearly negative departure (Raphael Pharmaceutical's chairman and CFO resignations) and one mixed event (Cloudastructure's failed authorized share decrease). Insider trading activity is absent, but forward-looking statements in 12 filings point to upcoming catalyst events, including leadership transitions, compensation milestones, and option repricings. The aggregate data suggests a market environment where companies are proactively refreshing boards and retaining talent amid sector-specific tailwinds in energy, mining, and AI infrastructure.

42 high priority 42 total filings
· daily

USA Insider Trading Pulse — July 17, 2026

The July 17, 2026, insider trading pulse reveals a bifurcated market with significant capital deployment by large institutional holders in financials and real estate, contrasted by systematic insider selling in the technology sector. The most notable event is Sumitomo Mitsui Financial Group's massive $319M open-market purchase of Jefferies Financial Group, signaling strong conviction in the investment banking cycle. Concurrently, multiple Manulife entities collectively invested over $78M in John Hancock GA Mortgage Trust, indicating a bullish outlook on mortgage credit. On the bearish side, a cluster of C-suite executives at CIENA Corp executed pre-planned sales totaling over $3M, while a director at AEHR TEST SYSTEMS sold $1.64M post-gift, creating a negative technical signal. The day was dominated by routine equity awards (33 out of 50 filings), which are neutral but provide a baseline for tracking insider accumulation. A notable positive outlier is the CEO of Elevance Health, who deployed $753K of personal capital into the open market, a strong vote of confidence in the managed care sector. The data suggests a 'risk-on' rotation into financials and real estate, while tech insiders are taking profits.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 17, 2026

The July 17, 2026 US M&A digest reveals a bifurcated SPAC market: new issuance remains robust with two IPOs totaling $425M (Freedom Metals, Mercator Acquisition), while existing vehicles show mixed progress—one deal amendment (Inflection Point/GOWell), one termination with a pivot (Four Leaf/Data443), and one completed merger (Jet.AI/flyExclusive). Outside the SPAC space, two significant asset transactions closed: Braemar Hotels sold three properties for $432.7M (netting a $158.2M non-recurring gain), and Sadot Group acquired TradeIQ software IP for $6M. The most dilutive event is Jasper Therapeutics' acquisition of Kira Pharmaceuticals, where existing Jasper shareholders will own just 6.68% of the combined entity post-$132M PIPE. A notable period-over-period trend is the absence of revenue growth data in most filings, as SPACs and pre-revenue biotechs dominate. Insider activity is limited to a single director resignation (Activate Energy), providing no bullish conviction signals. Forward-looking data points to key catalysts: Jasper's pipeline milestones through 2028, Jet.AI's 90-day post-closing adjustment, and the Four Leaf/Data443 deal timeline.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 17, 2026

Overnight SEC filings reveal a market bifurcated between aggressive capital deployment and fundamental deterioration. The most dominant theme is a wave of transformative M&A and capital markets activity, including NextEra Energy's $2.25 billion deal to acquire Dominion Energy, IPG Photonics' €300 million acquisition of Lumibird Medical, and Jasper Therapeutics' dilutive $132 million PIPE-funded merger with Kira Pharmaceuticals. However, this optimism is counterbalanced by severe operational stress in several sectors. Frequency Electronics reported a dramatic swing from a $23.7M profit to a $0.9M loss, while AITX's cash position dwindled to just $95K against $44.9M in current liabilities. Insider activity is sending mixed signals: a massive $319M purchase by Sumitomo Mitsui in Jefferies Financial Group signals strong institutional conviction, while a $1.8M sale by Marvell's Data Center President raises questions about peak valuation. The financial sector shows a clear divergence, with Truist and Fifth Third posting strong YoY earnings growth driven by fee income and M&A integration, while Regions Financial reported flat revenue and elevated net charge-offs. The SPAC market remains active but challenged, with Papaya Growth's cash trust depleting and Sigyn Therapeutics deregistering entirely, highlighting the ongoing shakeout in blank-check companies.

29 high priority 21 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — July 16, 2026

This digest covers $409 million in federal construction and infrastructure contracts awarded to three contractors, all from civilian agencies (HHS and VA), with zero defense-related awards. The dominant theme is healthcare facility modernization, led by Whiting-Turner's $302 million NIH Building 10 renovation, which is roughly 55% complete and signals steady institutional construction demand. The highest-conviction signal is the VA's dual SDVOSB set-aside awards to AMCOR JV ONE LLC ($58 million) and The Trevino Group ($49 million), reflecting sustained policy support for veteran-owned businesses in healthcare IT infrastructure. Key risks include fixed-price execution risk on the two VA contracts, particularly The Trevino Group's $48.9 million project with no outlayed funds yet, and the potential for budget disruptions from a continuing resolution given the October-December vulnerability window for civilian agency contracts.

3 total filings
· daily

DHS Homeland Security Contracts — July 16, 2026

This digest covers two civilian Department of Homeland Security (DHS) contracts totaling $147.6 million, with zero defense exposure, underscoring a stable but non-cyclical procurement environment for homeland security and telecom infrastructure. The highest-conviction signal is a bullish $73 million AT&T Enterprises award under the DHS Enterprise Infrastructure Solutions (EIS) program, which reinforces AT&T’s competitive position in federal telecom and offers a potential $133 million upside if options are exercised. A neutral $74.6 million Smiths Detection sole-source award for TSA explosive detection systems shows strong execution (70% funded) but carries fixed-price margin risk. Key watch items include TSA’s future procurement strategy for detection systems and DHS budget allocations for IT/telecom, which will determine option exercise likelihood.

2 total filings
· daily

VA Healthcare & Services Contracts — July 16, 2026

Over a single-day period, the Department of Veterans Affairs awarded two firm-fixed-price construction contracts totaling $106.9 million, both exclusively to Service Disabled Veteran Owned Small Businesses (SDVOSBs). The aggregate is entirely civilian (0% defense), reflecting sustained VA investment in healthcare IT infrastructure and facility modernization. The highest-conviction signal is the $58.1 million EHRM infrastructure upgrade award to AMCOR JV ONE LLC for San Juan, PR, which carries medium pricing risk due to its 3.4-year fixed-price structure. A key risk is that both contracts are fixed-price, transferring cost overrun exposure to small contractors with limited balance sheets, particularly for The Trevino Group's $48.9 million Houston facility project, which has high pricing risk and no outlayed funds yet.

2 total filings
· daily

HHS & Healthcare Contracts Intelligence — July 16, 2026

This digest covers a single $57.3 million civilian contract from the Department of Health and Human Services (HHS) to Harvard College, a non-profit educational institution, for tuberculosis immunity research under NIH/NIAID. The award is cost-no-fee, generating zero profit for the recipient, and carries a neutral signal strength of 1/10 with no defense-related exposure. The dominant theme is steady, non-commercial NIH funding for infectious disease research, which is immaterial to public equity investors. Key risk: this contract displaces no for-profit competitors and offers no direct investment catalyst. The aggregate total obligation is $57,273,777, with zero defense contracts and zero bullish or bearish signals identified.

1 total filings
· daily

New Federal Contractors — July 16, 2026

This digest of 20 new federal contracts, totaling $1.39 billion, reveals a heavily civilian-dominated procurement environment, with only one defense-related award (Northrop Grumman's $80.6M NASA MAPS contract) among the mix. The dominant themes are infrastructure modernization at HHS/NIH ($302M Whiting-Turner) and aviation surveillance at DOT/FAA ($70.7M L3Harris SBS II sole-source), alongside steady IT services wins for Booz Allen Hamilton ($109M combined) and Accenture Federal Services ($47M at DOE). The highest-conviction signal is L3Harris's $913.4M total potential SBS II contract, which provides multi-year revenue visibility and underscores its entrenched position in FAA surveillance. Key risks include execution pressure on fixed-price construction contracts (Whiting-Turner, Trevino Group) and the vulnerability of civilian agency awards to continuing resolution uncertainty in Q4 2026.

20 total filings